Psychedelic microdosing

1. Introduction

Version followed: there is no treatment manual for microdosing. This guide follows (i) the research frame of published placebo-controlled studies and trial protocols (Szigeti et al. 2021 self-blinding study; Marschall et al. 2022; the LSDDEP2 trial protocol, Trials 2024; Beidas, Petranker et al. 2026 protocol), with risks taken from Polito & Liknaitzky 2022, Tagen et al. 2023 and Nayak et al. 2021, and (ii) the harm reduction and integration therapy (HRIT) model of Pilecki et al. 2021, which this guide adapts to microdosing [synthesis]. It contains no amounts, schedules, routes, sourcing or administration detail, by design.

Sources include: Szigeti et al. 2021 (eLife), Marschall et al. (J Psychopharmacol, online 2021, issue 2022), Anderson et al. 2019 (Psychopharmacology survey), the LSDDEP2 registry entry and the published LSDDEP2 protocol (Trials 2024; monitoring and stopping rules), the Beidas et al. 2026 protocol body text, and the registered protocol of the adult ADHD trial reported by Mueller et al. 2025 (NCT05200936). Confirmed: published trials exclude people with a personal history of psychotic disorder, bipolar disorder or mania; the ADHD trial also excludes anyone with a first-degree relative with a psychotic disorder; LSDDEP2 excludes MAO inhibitors, pregnancy, lactation and cardiovascular conditions. Sources also include the Anderson et al. 2019 Harm Reduction Journal codebook and the Mueller et al. 2025 JAMA Psychiatry report, which itself states the exclusion of a past or present psychotic disorder in the participant or a first-degree relative. Still [uncertain]: whether other microdosing protocols exclude family history of psychosis, LSDDEP2 results (none posted), and legal status outside the US beyond the countries named below.

What it is. Microdosing is not a psychotherapy. It is a practice, mostly self-directed and outside the law, of repeatedly taking a classic psychedelic (most often psilocybin or LSD) at levels intended to stay below a full psychedelic experience, while going about ordinary life. In a codebook built from 278 microdosers' own reports, the most common benefit categories were improved mood, focus, creativity, self-efficacy and energy; the most common challenge was illegality (the authors include its knock-on effects: uncertain dosing with unregulated products, black-market access, cost, stigma and having to hide use), followed by physical discomfort [source: Anderson et al. 2019, Harm Reduction Journal 16:43]. In a preregistered online survey of 909 people (594 current or former microdosers), microdosers scored lower on dysfunctional attitudes and negative emotionality and higher on wisdom, open-mindedness and creativity; the authors stress the design is correlational, cannot show cause, and call for placebo-controlled trials [source: Anderson et al. 2019, Psychopharmacology]. Polito & Liknaitzky (2022) argue the word "sub-perceptual" is misleading: many users notice effects (in one survey over 70% sometimes felt "mildly tripping"), so they propose "sub-hallucinogenic" instead [source: Polito & Liknaitzky 2022].

Claimed mechanism, and what controlled studies show. Users and lay advocates attribute change to small cumulative pharmacological effects on mood and cognition. Controlled studies have so far found little or nothing beyond placebo:

Self-blinding citizen science (240 started, 191 completed): microdosers improved from baseline on well-being, mindfulness, life satisfaction and paranoia, but the placebo group also improved, and there were no significant between-group differences at the end of the regimen or at follow-up; cognition did not improve. Participants guessed their condition correctly 72% of the time, and scores were better when people believed they had taken the active substance, whatever they actually took. The authors conclude the benefits are "rather explained by the placebo effect" and note limits: unverified substances, self-report, a healthy sample, not a clinical trial [source: Szigeti et al. 2021, full text].
Double-blind, within-subject field and lab study (participants recruited via microdosing workshops in the Netherlands): no effect of psilocybin versus placebo on depression, anxiety or emotion processing, with Bayesian analyses favouring no effect; depression and stress fell from baseline in both conditions, which the authors call a non-specific, placebo-like effect. Participants broke blind in the second block [source: Marschall et al. 2022, full text].
Randomised trial in adult ADHD (53 adults, Basel and Maastricht; NCT05200936): symptoms improved slightly more on placebo than on repeated low-dose LSD, with no significant difference; adverse events were about twice as common with LSD (124 vs 64 events; treatment-related 23 vs 8), none serious [source: Mueller et al. 2025, JAMA Psychiatry].
Open-label phase 2a study in depression (19 participants, New Zealand, no control group): short-term mood improvements that the authors say need confirmation in controlled trials [source: Daldegan-Bueno et al. 2026, AUT repository abstract].

Polito & Liknaitzky caution that calling the effects "mainly expectancy" is premature, since lab studies tested acute effects while users report cumulative ones [source: Polito & Liknaitzky 2022]. Placebo-controlled trials in major depression are registered or under way: LSDDEP2 in New Zealand (no results posted on the registry when checked) and a psilocybin trial in Ontario (NCT05259943) [source: ANZCTR LSDDEP2 record; Beidas et al. 2026]. Results of these two trials are not reported in the sources cited [uncertain].

The clinician's role. For a psychotherapist, the "modality" is therefore your structured response to a client who microdoses or is thinking about it: nonjudgmental assessment, risk screening, balanced education, harm reduction, monitoring, integration of what the client learns, and referral. You do not supply, recommend, dose, schedule or supervise use [source: Pilecki et al. 2021; MDedge 2024].

Legal and regulatory status (as of the sources' dates, 2023–2026; check current law). United States: psilocybin and LSD stay illegal under federal law and in most states. Oregon runs licensed psilocybin services; its rules set the minimum length of an administration session by the amount consumed, with the shortest minimum for the lowest tier (the rule does not use the word "subperceptual"), so microdosing there can happen legally only inside licensed sessions [source: OAR 333-333-5250]. Many Oregon counties and cities voted to ban those services [uncertain: secondary, unverified; source: The Microdose newsletter, Jan 2023]. Colorado's Proposition 122 created a regulated natural-medicine programme, with licence applications from late 2024; about two dozen US localities have decriminalised [source: The Microdose; MDedge 2024]. Australia: from 1 July 2023 psilocybin moved to Schedule 8 for one use only: approved psychiatrists under the Authorised Prescriber Scheme may use it for treatment-resistant depression, with an ethics-approved protocol, in supervised clinical settings and not for home use; otherwise it remains prohibited (Schedule 9) [source: The Regulatory Review]. Self-directed microdosing therefore has no legal route there [synthesis from that source]. Canada: individual permits through the Special Access Program for selected patients; microdosing research runs under Health Canada clinical-trial rules [source: The Regulatory Review; Beidas et al. 2026]. Switzerland: an exceptional-permit pathway for limited compassionate use [source: The Regulatory Review]. New Zealand: microdosing only inside ethics-approved trials such as LSDDEP2 [source: ANZCTR]. Netherlands: dried psilocybin mushrooms are illegal; truffles sit in a legal grey zone with no therapeutic framework. Portugal: personal possession of drugs is decriminalised (not legalised). Jamaica: psilocybin mushrooms are reported to be legal [source for these three: HealingMaps, a secondary site updated 2026; not checked against national law, so treat as [uncertain]]. LSD is not an approved medicine anywhere as of mid-2026 [source: HealingMaps]. Status in the UK, Germany, other EU states and elsewhere is not covered here [uncertain].

2. Framework

The stages below are a clinician's framework built on the HRIT model (pre-use harm reduction, then post-use integration) and on how trials screen and monitor participants. The staging, session counts and transition criteria are [synthesis]; the content of each stage is sourced as marked.

Stage A. Disclosure and engagement (usually part of 1 session). Goal: the client feels safe telling you about use or plans. Method: open, nonjudgmental questions as part of routine substance and medication review [source: MDedge 2024, Grinspoon]. Move on when: you know the substance, how long the client has been using or planning, and why.

Stage B. Assessment and screening (1–2 sessions). Goal: identify psychiatric, medical and medication risks and the unmet need behind the interest. Content: motivation [source: MDedge, Yehuda; Pilecki et al. 2021]; personal history of psychotic disorder, schizophrenia, bipolar disorder, mania or hypomania, which published microdosing trials exclude [source: ANZCTR LSDDEP2; Marschall et al. 2022; Beidas et al. 2026; NCT05200936 protocol]; family history of psychosis, which the adult ADHD microdosing trial excludes (a first-degree relative with a psychotic disorder) [source: NCT05200936 protocol; Mueller et al. 2025]; past suicide attempts and current suicidal ideation (structured risk assessment, e.g. the C-SSRS, as in trials); substance-use disorder; psychotropic and serotonergic medication and supplements, including MAO inhibitors [source: ANZCTR LSDDEP2; Beidas et al. 2026]; lithium [source: Nayak et al. 2021]; cardiac history [source: Tagen et al. 2023; ANZCTR LSDDEP2]; pregnancy or breastfeeding [source: ANZCTR LSDDEP2]. Move on when: risks are documented and any medication question has gone to the prescriber.

Stage C. Education and shared deliberation (1–2 sessions). Goal: an informed, autonomous decision, which may be to not start, to stop, to continue, or to join a trial. Content: what controlled trials found, known adverse effects, unknown long-term safety, risks of an unregulated supply, legal risk, and alternatives (psychotherapy, approved medication, clinical trials) [source: Pilecki et al. 2021; Szigeti 2021; Polito & Liknaitzky 2022]. Move on when: the client can state the main risks and the evidence in their own words.

Stage D. Safety planning (1 session, only if the client chooses to continue). Goal: reduce harm without facilitating. Content: stop and seek-help criteria, interaction checks with the prescriber, drug-checking information, no driving or safety-critical work while any effect is felt, a support person [source: Pilecki et al. 2021, adapted; driving and work points adapted for microdosing are synthesis].

Stage E. Monitoring (brief check-ins inside ongoing therapy). Goal: notice adverse effects (sleep, anxiety, overstimulation, mood elevation, physical symptoms) and measure change honestly. Content: standard symptom measures and the client's own observations [source: adverse-effect list from Polito & Liknaitzky 2022; measurement approach is synthesis].

Stage F. Integration and review (1–3 sessions, and when use stops). Goal: help the client make sense of what changed, credit their own effort, turn insights into habits, and decide next steps [source: Pilecki et al. 2021 integration stage; the focus on attribution is synthesis].

Format. Individual sessions inside ongoing psychotherapy; no session is held while the client is under the influence (HRIT recommends that informed consent set out what happens if a client arrives intoxicated) [source: Pilecki et al. 2021]. Stages can loop: new medication, a new diagnosis or an adverse event sends you back to B.

Research frame (for clinicians referring to or working in trials). Trials screen with structured diagnostic interviews. LSDDEP2 (University of Auckland; ages 21–65; DSM-5 major depression) excludes current or past schizophrenia or other psychotic disorder, bipolar I or II, PTSD, eating disorders, suicide risk on the C-SSRS, recent substance dependence, problem drinking, more severe treatment-resistant depression, planned or current pregnancy or lactation, cardiovascular conditions including abnormal heart rate or blood pressure, abnormal ECG or laboratory results, MAO inhibitors and certain stimulants, a heavy medication burden judged by the study physician, and prior psychedelic microdosing or recent psychedelic use; people who could become pregnant must use effective contraception [source: ANZCTR LSDDEP2]. Participants may stay on existing antidepressants but may not start new depression treatment after enrolment [source: Daldegan-Bueno et al. 2024, LSDDEP2 protocol]. The Ontario psilocybin trial (ages 18–65, mild to moderate depression) excludes mania or hypomania history, past suicide attempts or active ideation, and current psychotropic, opioid or serotonergic medication, and requires washouts managed by the study physician [source: Beidas et al. 2026]. Earlier studies excluded current or past schizophrenia, psychosis, mania or borderline personality disorder, substance-use disorders and current medication [source: Marschall et al. 2022]. The adult ADHD trial excluded a past or present primary psychotic disorder or a first-degree relative with a psychotic disorder, past or present bipolar disorder, any lifetime suicide attempt, active suicidal ideation on the C-SSRS, substance use disorder (except nicotine), severe or untreated cardiovascular disease, and pregnancy or breastfeeding [source: NCT05200936 protocol (MindMed MMED007); Mueller et al. 2025]. By contrast, the self-blinding study did not screen out psychiatric diagnoses [source: Szigeti et al. 2021], so its safety findings do not apply to higher-risk groups [synthesis]. Trials monitor suicidality and vital signs at every visit, record adverse events, and give participants an exit plan with referral at the end or on withdrawal [source: Beidas et al. 2026]. LSDDEP2 is double-dummy, triple-blind and uses an active placebo, with participants in their everyday environment; adverse events are logged in a study app between visits and by staff on site, an independent data monitoring committee reviews data every six months, and the study drug is stopped at once if the participant asks, a serious adverse event occurs, an exclusion criterion appears, or clinicians judge that day-to-day functioning is likely to be affected; participants may withdraw at any time [source: Daldegan-Bueno et al. 2024, LSDDEP2 protocol]. Medical monitoring is the responsibility of the trial's medical staff.

3. Guiding principles

Nonjudgment and openness [source: MDedge 2024; Pilecki et al. 2021]. Meaning: ask about it routinely and neutrally; criticism makes clients stop disclosing.
Neither advocate nor opponent; respect autonomy [source: Pilecki et al. 2021]. Meaning: the client decides; your job is accurate information and safety.
Curiosity about the unmet need [source: MDedge, Yehuda]. Meaning: ask what current treatment is not giving them before discussing the substance.
Do not get ahead of the data [source: MDedge 2024; Polito & Liknaitzky 2022]. Meaning: say plainly that controlled studies have not shown benefit beyond placebo and that long-term safety is unknown.
No facilitation [source: Pilecki et al. 2021]. Meaning: no sources, sellers, guides, amounts, schedules or supervised use; avoid words like "guide" or "preparation" that suggest you facilitate.
Medication questions go to the prescriber [source: Pilecki et al. 2021]. Meaning: you name the general concern (for example lithium); the prescriber assesses it.
Competence and consultation [source: Pilecki et al. 2021]. Meaning: get training, supervision or peer consultation; training standards are not yet clear.
Know the law and know yourself [source: Pilecki et al. 2021, their phrase]. Meaning: check local drug law, your licensing board's view and your own risk tolerance before offering this work.
Clear scope in writing [source: Pilecki et al. 2021]. Meaning: a separate consent document saying what you do and do not do, and the plan if a client arrives under the influence.
Expectancy-aware honesty [synthesis, drawing on Szigeti 2021]. Meaning: treat improvement as real, but help the client see how much may come from expectation and their own actions.
Standard risk practice takes precedence [synthesis]. Meaning: suicide risk, mania and psychosis screening and response follow your usual protocols whatever the client's view of the substance.

4. Intervention inventory

No founder or manual sets out microdosing-specific clinical techniques. The interventions below are the clinician actions that the cited sources recommend (HRIT; MDedge clinician guidance; trial screening and monitoring), adapted to microdosing. Each is tagged. All example language is illustrative.

4.1 Routine, nonjudgmental inquiry

Purpose / when: at intake and whenever you review substances, supplements or medication; also when a client mentions "natural" or "low-dose" remedies. [source: MDedge 2024; Pilecki et al. 2021]
Steps: (1) Ask about psychedelics, including low-level or microdosing use, in the same tone as alcohol or caffeine. (2) Ask what substance, for how long, and why; do not ask for amounts unless you need them for a medical referral, and if so pass them to the prescriber without advising. (3) Reflect back without evaluating. (4) Say what you can and cannot help with (see 4.14).
Example language (illustrative): "Some people I work with take small amounts of psychedelics to help with mood or focus. Is that something you've tried or thought about?" / "Thanks for telling me. I'm not here to judge it. I'd like to understand what you hope it will do."
Watch for: guarded or minimising answers (go slowly, normalise); disclosure of other substance use that changes the risk picture. Working: the client brings it up again on their own.

4.2 Exploring motivation and the unmet need

Purpose / when: before any education; the reason behind microdosing often points to the real clinical target. [source: MDedge, Yehuda; Pilecki et al. 2021, clarifying why the client wants it]
Steps: (1) Ask what problem it is meant to solve (low mood, focus, creativity, burnout, side effects of medication, wish for spiritual growth). (2) Ask what has and has not helped so far. (3) Ask what they would notice if it worked. (4) Write down the client's own goals in measurable terms; these anchor 4.7 and 4.12.
Example language (illustrative): "What is it about the way things are now that makes this appealing?" / "If it did exactly what you hope, what would be different on a Tuesday afternoon?"
Watch for: dissatisfaction with current treatment that has not been raised with the prescriber; productivity pressure at work [synthesis]. Working: the goals become things therapy can also target.

4.3 Reviewing alternatives

Purpose / when: after 4.2, as part of informed decision-making. [source: Pilecki et al. 2021, alternatives such as psychotherapy, approved medications, clinical trials or ketamine treatment]
Steps: (1) Map each goal to evidence-based options (a specific psychotherapy, a medication review, behavioural activation, sleep or exercise work). (2) Mention clinical trials as a legal, monitored route. (3) Do not push; list options and let the client weigh them.
Example language (illustrative): "For low mood there are several things with solid evidence that we could add. And if you're interested in psychedelics specifically, research trials are one way to try them with medical oversight."
Watch for: the client hearing this as you disapproving (see rupture, section 5).

4.4 Psychiatric risk screening

Purpose / when: before or soon after disclosure; repeat if mood changes. Trials use these criteria to exclude people at higher risk. [source: Beidas et al. 2026 exclusions]
Steps: (1) Ask about any past mania or hypomania (use a structured interview or checklist). (2) Do a standard suicide risk assessment (trials use the C-SSRS), including past attempts and current ideation. (3) Ask about personal history of psychosis, schizophrenia or bipolar disorder; trials exclude these [source: ANZCTR LSDDEP2; Marschall et al. 2022; NCT05200936 protocol]. Also ask about psychotic disorder in first-degree relatives, which the adult ADHD microdosing trial excludes [source: NCT05200936 protocol]; the other microdosing protocols cited do not list it [uncertain]. (4) Ask about other substance use and any substance-use disorder, also a trial exclusion [source: Marschall et al. 2022; NCT05200936 protocol]. (5) Record findings and, where risk is raised, say clearly that this is the group trials exclude.
Example language (illustrative): "Research studies on microdosing don't accept people who've had psychosis, bipolar disorder, manic episodes or a recent suicide attempt, because the risks for them aren't known. I'd like to check those things with you."
Watch for: sleep loss with rising energy or racing thoughts (possible mood elevation); new or worse suicidal thoughts. Act on these through standard pathways.

4.5 Medication and medical interaction review, with referral

Purpose / when: for every client taking prescribed medication or supplements, or with cardiac history. [source: Pilecki et al. 2021, refer interaction questions to a prescriber; Nayak et al. 2021; Tagen et al. 2023; King, Psychopharmacology Institute]
Steps: (1) List current medication and supplements. (2) Flag the general concerns the sources name: lithium together with classic psychedelics was linked to seizures in almost half of 62 online reports (lamotrigine reports had none); the authors call this a provisional but serious risk [source: Nayak et al. 2021]. Antidepressants (SSRIs and SNRIs) may blunt effects; recent small studies are mixed [source: King]. Some antipsychotics block the target receptor [source: King]. As a general category, trials exclude MAO inhibitors and some stimulants [source: ANZCTR LSDDEP2], current psychotropic and serotonergic medications [source: Beidas et al. 2026], or any current medication [source: Marschall et al. 2022]. Serotonergic supplements (Beidas et al. list abbreviations for 5-HTP and SAM-e in their exclusion table) appear to be covered too [uncertain]. (3) Raise the cardiac concern as an attributed theoretical risk: Tagen et al. argue that repeated use could stimulate the 5-HT2B receptor, which has been linked to heart valve disease with other drugs; no study has tested this directly in microdosers [source: Tagen et al. 2023; Polito & Liknaitzky 2022]. LSDDEP2 excludes people with cardiovascular conditions or an abnormal ECG [source: ANZCTR LSDDEP2]. (4) With consent, refer the client to the prescriber or GP for an individual assessment. (5) Never advise stopping or changing prescribed medication yourself.
Example language (illustrative): "There's one combination researchers are especially worried about, lithium and psychedelics, because of seizure reports. That's a conversation to have with your prescriber before anything else."
Watch for: a client planning to stop antidepressants to "make room" for microdosing (risk of discontinuation symptoms and relapse; refer urgently to prescriber) [synthesis].

4.6 Balanced psychoeducation on the evidence

Purpose / when: Stage C; whenever the client cites claims from media or forums. [source: Pilecki et al. 2021, separating information from misinformation; Szigeti 2021; Marschall 2022; Polito & Liknaitzky 2022]
Steps: (1) Ask what they have read or heard. (2) Summarise plainly: survey studies report better mood, focus and creativity, but cannot show cause [source: Anderson et al. 2019]; placebo-controlled studies have mostly found that placebo groups improve just as much, in healthy users, in people with low mood and in adults with ADHD [source: Szigeti et al. 2021; Marschall et al. 2022; Mueller et al. 2025]; reviewers say expectancy matters but is not the whole answer, and controlled depression trials are still in progress [source: Polito & Liknaitzky 2022; ANZCTR LSDDEP2]. (3) Name known adverse effects (4.9) and the unknown long-term risks (4.5). (4) Check understanding by asking the client to summarise.
Example language (illustrative): "In the best-controlled studies, people taking a placebo felt better too, about as much as those taking the real thing. That doesn't mean you're imagining your improvement. It means expectation and what you do differently may be doing much of the work."
Watch for: defensiveness (pace it, see section 5); over-reassurance from you. Working: the client can describe both the claims and the gaps.

4.7 Measurement-based self-observation

Purpose / when: for clients who continue, or who believe it is helping; gives a fairer test than memory. [synthesis, informed by the expectancy findings in Szigeti 2021 and Polito & Liknaitzky 2022]
Steps: (1) Take a baseline on a standard measure you already use (for example PHQ-9 or GAD-7) and the client's own goals from 4.2. (2) Repeat at regular sessions. (3) Ask the client to log sleep, mood, anxiety, and what else they did that day (exercise, social contact, work). (4) Review the data together, looking at both the substance and the client's own actions. This guide does not describe how to run a personal self-blinding procedure; if the client wants a controlled test, point them to research studies.
Example language (illustrative): "Let's track this the way we'd track any change, so we can see what's actually shifting and what else is going on at the same time."
Watch for: sleep scores falling, anxiety rising, or gains that track with other changes (new routine, therapy work) rather than with use.

4.8 Risks of unregulated supply and the law

Purpose / when: whenever use is outside a legal programme. [source: Anderson et al. 2019, Harm Reduction Journal (illegality, including uncertain dosing with unregulated products, was the most reported challenge); MDedge 2024 (adulteration, dose uncertainty); Pilecki et al. 2021 (drug checking)]
Steps: (1) Explain in general terms that illegal products can be mislabelled, contaminated or of unknown strength. (2) Explain that drug-checking services run by qualified staff are more reliable than home kits, and that kits may be illegal in some places [source: Pilecki et al. 2021]. (3) Note legal consequences (criminal, employment, immigration, professional licensing) in general terms and suggest the client get legal advice if worried [synthesis]. (4) Never recommend a source, seller or product.
Example language (illustrative): "With anything bought outside a regulated system, nobody can be sure what it is or how strong it is. That's one of the biggest risks people describe."
Watch for: requests for sources (decline, see section 5).

4.9 Adverse-effect monitoring and stop criteria

Purpose / when: at every session while the client is using, and for a while after stopping. [source: adverse-effect list from Polito & Liknaitzky 2022; MDedge 2024 (a patient who could not sleep for two weeks); stop criteria are synthesis]
Steps: (1) Ask briefly about the effects reported in studies: insomnia, headache, fatigue, nausea, overstimulation, physical discomfort, unusually vivid dreams, more anxiety or stress, dizziness, and feeling "mildly tripping"; some lab studies found raised blood pressure and other autonomic changes [source: Polito & Liknaitzky 2022]. In the ADHD trial, treatment-related adverse events were about three times as common with LSD as with placebo (23 vs 8 events; most often headache, nausea, fatigue, insomnia and visual changes), none serious; two participants on LSD stopped because of strong acute effects or effects that impaired daily functioning [source: Mueller et al. 2025, JAMA Psychiatry]. (2) Ask about mood elevation, suicidal thoughts and unusual perceptions or beliefs [synthesis]. (3) Agree stop-and-contact criteria in advance (for example: several nights of poor sleep, panic, rising energy with less need for sleep, unusual beliefs, chest pain, palpitations, shortness of breath, fainting or a seizure) [synthesis; trials likewise stop the study drug on request, on a serious adverse event, or when functioning is likely to be affected, source: LSDDEP2 protocol]. (4) Physical symptoms go to the GP or emergency services; you do not assess them medically.
Example language (illustrative): "If you notice any of these, the plan we agreed is to stop and let me or your doctor know. Chest symptoms or a seizure mean emergency care straight away."
Watch for: symptoms the client explains away as "part of the process". Working: the client reports early and acts on the plan.

4.10 Harm-reduction safety planning

Purpose / when: only when an informed client has decided to continue. [source: Pilecki et al. 2021 pre-use harm reduction, adapted; items marked synthesis are added for microdosing]
Steps: (1) Confirm the interaction check with the prescriber is done (4.5). (2) Agree no driving, operating machinery or safety-critical work while any effect is noticeable [adapted from Pilecki's "no driving"; work point is synthesis]. (3) Name a trusted person who knows and can help if something goes wrong [source: Pilecki et al. 2021]. (4) Give drug-checking information in general terms (4.8). (5) Agree the stop criteria (4.9) and an emergency plan. (6) Write the plan down and review it at check-ins. Do not discuss amounts, timing, frequency or combining substances.
Example language (illustrative): "I won't advise on how to take it, but I can help you plan for safety. Who would you call if you felt unwell?"
Watch for: pressure to turn the plan into a protocol (decline; section 5).

4.11 Integration and meaning-making

Purpose / when: when the client reports shifts in mood, insight or perspective, and when use ends. [source: Pilecki et al. 2021 integration: processing, meaning-making, turning insights into lasting change through creative methods, movement, time in nature and new practices]
Steps: (1) Invite a concrete description of what changed and when. (2) Explore meaning without adopting or rejecting the client's frame. (3) Pick one or two insights and turn each into a specific behaviour, scheduled and tracked. (4) Use the methods HRIT names (creative work, movement, time in nature, new practices) as fits the client. (5) Agree next steps, which may include stopping, more social contact or other therapy work [source: Pilecki et al. 2021].
Example language (illustrative): "You said you felt more patient with your kids. What did patience look like on those days, and what could help you do more of it?"
Watch for: big decisions made on the strength of brief feelings; spiritual framings, which belong to the client and should be explored, not confirmed or dismissed [synthesis].

4.12 Attribution review and self-efficacy consolidation

Purpose / when: whenever gains are credited wholly to the substance; at the end of use. Self-efficacy is one of the benefits users report [source: Anderson et al. 2019]; strong placebo responses in trials suggest expectation and behaviour matter [source: Szigeti 2021; Marschall 2022]. The technique itself is [synthesis].
Steps: (1) List the improvements. (2) For each, list what the client did (sleep, exercise, reaching out, focusing) that went with it. (3) Ask which of those actions they could keep without the substance. (4) Plan to keep the gains if use stops.
Example language (illustrative): "Whatever part the substance played, you're the one who went for the walk and called your brother. Those are yours to keep."
Watch for: feeling dependent on the substance to function; low mood when use stops. Working: the client describes the change as partly their own.

4.13 Referral to trials and regulated services

Purpose / when: for clients who want to try psychedelics with oversight, or who meet a trial's condition (such as depression). [source: Pilecki et al. 2021; LSDDEP2; Beidas et al. 2026; Oregon rules per The Microdose]
Steps: (1) Search trial registries (e.g. ClinicalTrials.gov, ANZCTR) with the client. (2) Explain that trials screen strictly and may require medication changes under the study physician's care, and that participants can withdraw at any point. (3) Where a licensed programme exists (e.g. Oregon), explain that it is the legal route there; you do not recommend particular providers [synthesis]. (4) Offer to coordinate with the trial team with consent.
Example language (illustrative): "If you want to explore this properly, a research trial means medical screening, monitoring and support afterwards."
Watch for: the client being excluded and feeling rejected; process this and return to 4.3.

4.14 Scope-of-practice and informed-consent document

Purpose / when: before doing harm reduction or integration work. [source: Pilecki et al. 2021]
Steps: (1) Write a separate consent document saying you offer education, safety planning and integration, and that you do not supply, source, recommend, dose, guide or attend use. (2) Include what happens if the client arrives under the influence (e.g. contacting an emergency contact and arranging safe transport) [source: Pilecki et al. 2021]. (3) Go through it and sign it. (4) Make sure your website and written materials say the same thing [source: Pilecki et al. 2021].
Example language (illustrative): "This explains what I can help with and what I can't, so we're both clear from the start."
Watch for: your language drifting toward "guide" or "preparation" [source: Pilecki et al. 2021].

4.15 Documentation, legal and professional boundaries

Purpose / when: ongoing. [source: Pilecki et al. 2021; MDedge 2024]
Steps: (1) Learn your local drug law and your licensing board's stance; consider advice from a local criminal defence lawyer [source: Pilecki et al. 2021]. (2) Record clinical facts (use, risks discussed, advice given, referrals) without needless detail that would add legal exposure for the client [synthesis]. (3) Keep a vetted, educational resource list and say it is not a treatment recommendation [source: Pilecki et al. 2021]. (4) Use consultation or supervision [source: Pilecki et al. 2021]. (5) Decide in advance how you will answer questions about your own use; a non-specific answer is one option [source: Pilecki et al. 2021].
Watch for: requests for referrals to underground guides, which the authors call high risk [source: Pilecki et al. 2021].

4.16 Acute presentation in session

Purpose / when: the client arrives under the influence, or reports acute anxiety, panic, suicidal thoughts or physical symptoms. [source: Pilecki et al. 2021 (intoxication plan); Beidas et al. 2026 (worsening symptoms or suicidality trigger psychiatric assessment and urgent or emergency referral); grounding steps are synthesis]
Steps: (1) Check safety and physical symptoms; call emergency services for chest pain, seizure, confusion or fainting. (2) For anxiety without medical red flags, use calm grounding (slow breathing, orienting to the room) [synthesis]. (3) Assess suicide risk with your standard tool. (4) Do not do deep therapy work; reschedule. (5) Follow the consent-document plan for getting home safely. (6) Review at the next session and update the safety plan.
Example language (illustrative): "Let's pause the session. I want to make sure you're safe and get you home safely, and we'll talk it through next time."
Watch for: persisting perceptual changes, mood elevation or suicidal thoughts in later days; refer for psychiatric assessment [synthesis].

4.17 Exit plan and follow-up

Purpose / when: when the client stops microdosing, leaves a trial, or ends therapy. [source: Beidas et al. 2026 (exit plan and referral on completion or withdrawal); applying it to clinical practice is synthesis]
Steps: (1) Review gains and how to keep them (4.12). (2) Check mood, sleep and anxiety after stopping. (3) Agree relapse warning signs and a plan. (4) Make referrals as needed (prescriber, psychiatry, trial team, substance-use service).

5. Handling problems

The sources say little about problems specific to microdosing. Except where tagged otherwise, the guidance below is [synthesis] built on the HRIT stance (Pilecki et al. 2021) and standard clinical practice.

Client asks you for amounts, schedules, "the best protocol" or a source. Decline clearly and warmly, and explain that this is outside your role and the law; give the interaction, supply and safety information instead (4.5, 4.8, 4.10). Never recommend sellers, websites or guides [source: Pilecki et al. 2021]. Illustrative: "That's not something I can advise on, but I can help you think through the risks and keep yourself safe."
Client asks you to be present, "guide" or check in during use. Decline; HRIT does not include attending or facilitating dosing [source: Pilecki et al. 2021]. Offer sessions only when the client is not under the influence.
Rupture after you share the placebo findings. Validate the improvement first, then present the evidence as describing groups, not the client. Ask for feedback ("Did that come across as me doubting you?") and repair. Go back to curiosity about their goals (4.2).
Client is sure it works and wants to stop prescribed medication. Do not argue about whether it works. Name the risk of stopping abruptly (discontinuation symptoms, relapse) and refer to the prescriber straight away; with consent, contact the prescriber.
Lithium, recent mania or hypomania, bipolar disorder, past suicide attempt, current suicidal ideation, a psychosis history, or psychosis in a first-degree relative. Say plainly that these are the groups research excludes or where serious harm has been reported [source: Nayak et al. 2021; Beidas et al. 2026; ANZCTR LSDDEP2; Marschall et al. 2022; NCT05200936 protocol]; advise against use, involve the prescriber or psychiatrist, and increase monitoring. If suicidal thoughts are present, follow your suicide-risk protocol and give crisis contacts (988 in the US; Samaritans 116 123 in the UK and Ireland) [synthesis].
Adverse effects that the client minimises (insomnia, anxiety, overstimulation). Go back to the data from 4.7 and the stop criteria from 4.9. Remind them of reports such as two weeks without sleep [source: MDedge 2024]. Prolonged insomnia with rising energy calls for a mood assessment.
Escalation: more frequent use, larger amounts, or moving to full psychedelic experiences. Explore what is driving it (no effect, tolerance, chasing feelings). Re-screen (4.4, 4.5), revisit alternatives and trials, and treat it as you would any change in substance use; refer to substance-use services if use is compulsive or combined with other drugs. Microdosers in one survey reported more recreational substance use [source: Polito & Liknaitzky 2022].
Non-adherence to the safety plan (e.g. driving, using at work, skipping the prescriber check). Review it without blame, find the barrier, simplify the plan, and record the discussion. If a third party is at immediate risk, follow your local duty-to-protect rules.
Stuck: no change in therapy while the client waits for the substance to work. Use 4.12 to move the focus to behaviour change, and set therapy goals that do not depend on the substance.
Disappointment, or low mood when use stops. Normalise; check for relapse with standard measures; use 4.12 and 4.17.
Long-term use and heart health. Share the valve concern as a theoretical risk that Tagen et al. (2023) raise from 5-HT2B receptor pharmacology, not a documented harm in microdosers [source: Tagen et al. 2023]; trials exclude people with cardiovascular conditions or abnormal ECGs [source: ANZCTR LSDDEP2]. Suggest a GP review for anyone with heart disease or symptoms; the source does not recommend routine heart scans, so leave that decision to the doctor.
Pregnancy, breastfeeding, adolescents, older adults with medical conditions. Trials exclude planned or current pregnancy and breastfeeding and require effective contraception [source: ANZCTR LSDDEP2; NCT05200936 protocol], and enrol adults only (21–65 in LSDDEP2, 18–65 in the Ontario and ADHD trials) [source: ANZCTR LSDDEP2; Beidas et al. 2026; Mueller et al. 2025]. The sources cited give no microdosing safety data for pregnancy, breastfeeding or people under 18 [uncertain]. Advise against use in these groups and refer for medical advice; with a minor, follow your usual safeguarding and parental-involvement rules [synthesis].
Workplace pressure ("everyone in my team does it"). Explore values and pressures, and the legal and employment risks; work on stress, workload and focus with evidence-based methods.
Spiritual or mystical meanings the client attaches to use. Treat them as the client's or their tradition's own view: explore, do not confirm or dismiss, and refer to a trusted religious or cultural adviser if the client wants that.
Microdosing "workshops", retreats or coaches. Participants in one trial were recruited from a microdosing workshop [source: Marschall et al. 2022]. Help the client judge any such provider: their legal status, screening, emergency plans, claims, and whether they put pressure on people; the client can always decline or leave [source: Pilecki et al. 2021 on assessing guides, applied here].
Your own legal or ethical uncertainty. Get consultation, check your licensing board's position, and if needed get legal advice before continuing [source: Pilecki et al. 2021].

Sources

Web sources:

Not covered: Table 1 of Beidas et al. 2026 and national legislation outside the US and Australia. Claims from these are marked [uncertain] where relevant.

← Previous · VII-068Psychedelic group therapy Next · VII-070 →Psychedelic retreats and tourism